An interventional study of Dialectical Behavior Therapy -Skill Training brief intervention in Smoking Behavior, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Smoking by Wake Forest University Health Sciences — 2 open to participants now, 3 under way, none of them phase 3. Smoking · Wake Forest University Health Sciences.
Among the 10 studies in Smoking by Wake Forest University Health Sciences, this one is the only one that started in 2026, is one of 8 with no phase, and was the 10th registered.
1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.
Browse Smoking studies →2 of the 10 studies in Smoking by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 40–54 · Healthy volunteers
By country, each count listing its studies:
Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 116 across 1,167 interventional studies indexed under Smoking.
Median enrollment 66 across the 9 interventional studies, 0 across the 1 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
2 of the studies in Smoking by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07119489Wake Forest University Health SciencesA Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial | 2026-11 |
| NCT05790486Wake Forest University Health SciencesTake A Break - Rural | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Smoking by Wake Forest University Health Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to learn more about how Dialectical Behavior Therapy - Skills Training can help patients with cancer who smoke cigarettes cut down on or stop their smoking.
This is a study that aims to evaluate recruitment rates, feasibility, acceptability, and fidelity of Dialectical Behavior Therapy - Skills Training (DBT-ST) brief intervention.
Study population will include participants who smoke and are undergoing treatment with curative intent for their cancer or are in remission.
The study will include eight 60 minute sessions of DBT-ST and measurements of psychological states and smoking habits by interventionists. At follow-up participants will complete a survey on their intervention experience and ongoing use of DBT-ST. Interventionists will also complete a survey following each session to record time and materials use for future cost-effectiveness analysis.
At follow-up, participants and interventionists will engage in a one-hour qualitative interview with a study team member.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who smoke and are undergoing treatment with a curative intent for cancer or are in remission from cancer
Behavioral: Dialectical Behavior Therapy -Skill Training brief intervention
A behavioral counseling approach for enhancing skills in emotion regulation, distress tolerance, and mindfulness
Recruitment Rates
Ratio of patients enrolled in study to patients responding to advertisement or referred by providers, and ratio of patients enrolled to patients screened and potentially eligible for the study.
Time frame: Measured from the date the first patient responds to advertisement or is referred to the study by providers until the date the last patient group begins the first session of the intervention, assessed up to 100 weeks.
Feasibility of the DBT-ST brief intervention for cigarette smoking by patients with cancer
Rate of completion of the eight proposed sessions by participants
Time frame: Measured from the date the first patient group begins the first session of the intervention until the date the last patient group completes the eighth session of the intervention, assessed up to 100 weeks.
Acceptability of the DBT-ST brief intervention for cigarette smoking by patients with cancer
Quantitative (Likert scale) questions to assess patient experience of intervention
Time frame: For each patient group, measured at weeks 1 through 8 of the intervention and at 1 month follow-up, assessed up to 100 weeks.
Fidelity of the DBT-ST brief intervention for cigarette smoking by patients with cancer
Interventionist adherence to intervention manual will be assessed by having an independent reviewer select 50% of the audiotaped group sessions (the total depends on the number of groups) and complete a checklist of 25 intervention items (yes/no) to see whether the interventionist performed the item
Time frame: Measured beginning 1 month after the date of week 8 of the final patient group participating in the intervention, assessed up to 6 months.
Cancer Patient Tobacco Use Questionnaire (C-TUQ)
Changes in tobacco use, specifically number of days engaging in cigarette smoking (frequency) and number of cigarettes smoked per day (daily average) will be measured using the Cancer Patient Tobacco Use Questionnaire (C-TUQ) a 22-item self-report survey used to gather information about tobacco use by patients with cancer and cancer survivors.
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Difficulties in Emotion Regulation Scale-36 (DERS-36)
The Difficulties in Emotion Regulation Scale (DERS) is a 36-item self-report Likert scale used to assess emotional regulation presented as a total score and 6 sub-scores including nonacceptance of emotional responses, difficulty engaging in goal-directed behavior, impulse control difficulties, lack of emotional awareness, limited access to emotion regulation strategies, and lack of emotional clarity
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Depression Anxiety Stress Scales-21 (DASS-21)
The DASS-21 is a 21-item self-report instrument designed to measure the three related negative emotional states of depression, anxiety, and tension/stress.
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Distress Tolerance Scale (DTS)
Distress tolerance will be measured using the 15-item Distress Tolerance Scale (DTS). The DTS uses a 5-point Likert scale for participants to record responses to items (1 = 'Strongly Agree' to 5 = 'Strongly Disagree'). The total DTS score is calculated by adding the scores of all 15 items together after reverse-coding item 6 (score range 0-75)
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Mindfulness Attention Awareness Scale (MAAS)
Mindfulness will be measured using the Mindfulness Attention Awareness Scale (MAAS), a 15-item self-report instrument designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present. The MAAS score is the mean of 15 Likert-scale items from 1-6 (score range 1-6)
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Mental Adjustment to Cancer (MAC) Scale - Mini
The MAC-Mini is a 29-item self-rating scale to assess psychological dimensions of in cancer patients of helplessness/hopelessness, anxious preoccupation, fatalism, avoidance, and fighting spirit in their adjustment to the diagnosis and treatment of cancer. Higher scores reflect lower levels of adjustment for all subscales except fighting spirit, with a higher score indicating higher adjustment
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
DBT Ways of Coping Checklist (DBT-WCCL)
The DBT-WCCL is a 59-item self-report Likert scale, with one part assessing coping via DBT skills, the DBT Skills Subscale (DSS), and one part assessing coping via dysfunctional means, the Dysfunctional Coping Subscale (DCS).44 Skills use are measured on a scale from 0 (never used) to 3 (regularly used). Higher scores indicate more frequent use of DBT skills and functional coping behaviors.
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Serious quit attempts
The period of intentional abstinence from smoking typically lasting at least 24 hours, to be collected by self-report using a single item Serious Quit Attempt questionnaire
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Self-reported cost for interventionist and patient time and expenses
Self-reported cost for interventionist and patient time and expenses will be collected using an interventionist questionnaire
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Costs of nicotine replacement therapy
Costs of nicotine replacement therapy will be captured using a single item added to the Cancer Patient Tobacco Use Questionnaire (item 15a)
Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.
Time between initial cancer diagnosis and administration of the DBT-ST intervention
The impact on smoking cessation or reduction of the length of time between initial cancer diagnosis and administration of the DBT-ST intervention will be measured using the initial diagnosis date of any cancer per the patient's electronic health record and the Cancer Patient Tobacco Use Questionnaire
Time frame: Measured from the date of initial cancer diagnosis until week 1 of the patient's participation in the intervention, assessed up to 100 weeks.
Group Size
The impact of group size on outcomes will be measured using the number of persons in each group, provided group size varies
Time frame: Measured beginning 1 month after the date of week 8 of the final patient group participating in the intervention, assessed up to 6 months.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.
Of 405 non-industry interventional studies with no phase under Smoking, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 9 months is below that.
Counting every sponsor, half of 461 studies reached it within 23 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →